Shanghai Hanhong Scientific Co., Ltd. was established in 2003, headquartered in the National University Science and Technology Park of East China University of Science and Technology. It is a high-tech enterprise engaged in the production of drug molecular blocks, drug intermediates and active pharmaceutical ingredients, and providing CRO and CDMO services. The company currently has total assets of 150 million yuan, net assets of over 80 million yuan, and 150 employees, including 4 PhDs, 12 masters, and over 70 undergraduates; The sales revenue for 2022 is 210 million yuan. The company is a specialized and innovative enterprise in Shanghai, and a national high-tech enterprise.

Hanhong Technology focuses on the field of biomedicine and has always been committed to independent technological innovation. After years of technological accumulation, it has formed core technological advantages in areas such as biocatalysis, chiral chemistry, and green synthesis. The company has established a research and development center in Fengxian, Shanghai, with an area of 2200 square meters and over 40 research and development personnel; The company has established production bases in Binhai, Jiangsu, Gaotang, Shandong, and Lanzhou, Gansu, with a total of over 300 reaction vessels. Hanhong's non natural amino acids, protected amino acids, and amino acid derivative series intermediates have core competitiveness and a high market share.

Hanhong Technology takes innovation as its core driving force, focuses on the amino acid derivative industry chain, relies on the company's research and development capabilities and production facilities, focuses on drug research and development and drug production, and provides customers with integrated products and services from drug molecular blocks, pharmaceutical intermediates to active pharmaceutical ingredients.